- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cipla US unit recalls 6 batches of Albuterol sulfate inhalation aerosol over container defect
Cipla said there were no adverse events reported for the inhaler related to the recall.
Bengaluru: Indian drugmaker Cipla said on Friday its U.S. unit was recalling six batches of albuterol sulfate inhalation aerosol due to a "container defect".
"The company is initiating a recall in the U.S. due to a market complaint for one single inhaler, where leakage was observed through the inhaler valve," the pharmaceutical company said in a statement.
The six batches, manufactured in November 2021 using the same lot of valves, are being recalled, the company added.
The company’s "Albuterol Sulfate HFA Inhalation Aerosol” is a generic therapeutic equivalent version of an inhaler from Merck & Co, according to Cipla’s website.
Cipla said there were no adverse events reported for the inhaler related to the recall.
But a failure to deliver the recommended dose to treat the respiratory symptoms of acute asthma exacerbations, including wheezing and bronchospasms, due to a device defect, could be "life-threatening", Cipla added.
Read also: Cipla recalls Solifenacin Succinate tablets in US over manufacturing issues
Albuterol sulfate inhalation aerosol is used for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Cipla also said consumers should stop using, return to place of purchase or discard the inhalers. It also added that adverse reactions with the use of the product could be reported to the U.S. health agency.
Read also: Sun Pharma recalls pre-filled syringes of infertility drug in US over manufacturing issue
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751